Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.

Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, Fox BA.

J Transl Med. 2013 Mar 3;11:54. doi: 10.1186/1479-5876-11-54.

2.

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types.

Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD.

Clin Cancer Res. 2013 Mar 1;19(5):1009-20. doi: 10.1158/1078-0432.CCR-12-2982.

3.

Prognostic and predictive markers for the new immunotherapies.

Mahoney KM, Atkins MB.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:39-48. Review.

4.

Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015.

Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M.

J Transl Med. 2016 Sep 20;14:273. doi: 10.1186/s12967-016-1029-z.

5.

The immune score as a new possible approach for the classification of cancer.

Galon J, Pagès F, Marincola FM, Thurin M, Trinchieri G, Fox BA, Gajewski TF, Ascierto PA.

J Transl Med. 2012 Jan 3;10:1. doi: 10.1186/1479-5876-10-1.

6.
7.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

8.

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.

Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ.

J Immunotoxicol. 2012 Jul-Sep;9(3):248-58. doi: 10.3109/1547691X.2012.685527. Review.

PMID:
22734880
9.

CD40 activation as potential tool in malignant neoplasms.

Ottaiano A, Pisano C, De Chiara A, Ascierto PA, Botti G, Barletta E, Apice G, Gridelli C, Iaffaioli VR.

Tumori. 2002 Sep-Oct;88(5):361-6. Review.

PMID:
12487551
10.

[Intratumoral immune microenvironment and survival: the immunoscore].

Galon J, Bindea G, Mlecnik B, Angell H, Lagorce C, Todosi AM, Berger A, Pagès F.

Med Sci (Paris). 2014 Apr;30(4):439-44. doi: 10.1051/medsci/20143004020. Review. French.

11.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
12.

Biomarkers for Immunotherapy: Current Developments and Challenges.

Spencer KR, Wang J, Silk AW, Ganesan S, Kaufman HL, Mehnert JM.

Am Soc Clin Oncol Educ Book. 2016;35:e493-503. doi: 10.14694/EDBK_160766.

13.

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P.

Cancer Immun. 2007 Jun 26;7:10. Review.

14.

New developments in biomarkers for melanoma.

Griewank KG, Ugurel S, Schadendorf D, Paschen A.

Curr Opin Oncol. 2013 Mar;25(2):145-51. doi: 10.1097/CCO.0b013e32835dafdf. Review.

PMID:
23334230
15.

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.

Bodey B, Siegel SE, Kaiser HE.

Anticancer Res. 1996 Mar-Apr;16(2):661-74. Review.

PMID:
8687112
16.

Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer.

Bitting RL, Armstrong AJ.

Cancer J. 2013 Jan-Feb;19(1):25-33. doi: 10.1097/PPO.0b013e31827e0b9c. Review.

PMID:
23337754
17.

From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.

Angell H, Galon J.

Curr Opin Immunol. 2013 Apr;25(2):261-7. doi: 10.1016/j.coi.2013.03.004. Review.

PMID:
23579076
18.

[Biomarkers for cancer immunotherapy].

Kawakami Y, Kawase Y, Ohizumi A, Noji S, Sakurai T, Fujita T.

Nihon Rinsho. 2012 May;70(5):759-66. Review. Japanese.

PMID:
22619998
19.

Targeting the immune system in cancer.

Chaudhuri D, Suriano R, Mittelman A, Tiwari RK.

Curr Pharm Biotechnol. 2009 Feb;10(2):166-84. Review.

PMID:
19199949
20.

Toward integrative cancer immunotherapy: targeting the tumor microenvironment.

Emens LA, Silverstein SC, Khleif S, Marincola FM, Galon J.

J Transl Med. 2012 Apr 10;10:70. doi: 10.1186/1479-5876-10-70.

Supplemental Content

Support Center